Ascentage Pharma Group International - American Depository Shares (AAPG)

On Thursday, Ascentage Pharma Group (NASDAQ:AAPG) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive

Ascentage Pharma Group International (NASDAQ:AAPG) reported first-half 2026 revenue growth as it continued investing in global registrational studies for its hematology-oncology pipeline and began building commercial capabilities outside China. Total revenue for the six months ended June 30 was $44

U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed.

Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment.

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more growth as 36 IPOs have already been priced this year, including Diginex's 600% return.